BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Nishimoto A. Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment. World J Gastroenterol 2022; 28(28): 3637-3643 [PMID: 36161054 DOI: 10.3748/wjg.v28.i28.3637]
URL: https://www.wjgnet.com/1007-9327/full/v28/i28/3637.htm
Number Citing Articles
Tianqi Xu, Alexey Schulga, Elena Konovalova, Sara S. Rinne, Hongchao Zhang, Olga Vorontsova, Anna Orlova, Sergey M. Deyev, Vladimir Tolmachev, Anzhelika Vorobyeva. Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft ModelInternational Journal of Molecular Sciences 2023; 24(3): 2838 doi: 10.3390/ijms24032838
Jay Natu, Ganji Purnachandra Nagaraju. Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: Special focus on resistance mechanisms and metronomic therapiesCancer Letters 2023; 573: 216382 doi: 10.1016/j.canlet.2023.216382
Priti Gupta, Charles F. Hodgman, Claudia Alvarez-Florez, Keri L. Schadler, Melissa M. Markofski, Daniel P. O’Connor, Emily C. LaVoy. Comparison of three exercise interventions with and without gemcitabine treatment on pancreatic tumor growth in mice: No impact on tumor infiltrating lymphocytesFrontiers in Physiology 2022; 13 doi: 10.3389/fphys.2022.1039988
Jun-Hao Huang, Wei Guo, Zhe Liu. Discussion on gemcitabine combined with targeted drugs in the treatment of pancreatic cancerWorld Journal of Gastroenterology 2023; 29(3): 579-581 doi: 10.3748/wjg.v29.i3.579
Junliang Chen, Zhihao Liu, Zhiyuan Wu, Wenjun Li, Xiaodong Tan. Identification of a chemoresistance-related prognostic gene signature by comprehensive analysis and experimental validation in pancreatic cancerFrontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1132424